CA2147754A1 - Compositions et methodes pour modifier l'activite de regulation de tgf- .beta. - Google Patents

Compositions et methodes pour modifier l'activite de regulation de tgf- .beta.

Info

Publication number
CA2147754A1
CA2147754A1 CA002147754A CA2147754A CA2147754A1 CA 2147754 A1 CA2147754 A1 CA 2147754A1 CA 002147754 A CA002147754 A CA 002147754A CA 2147754 A CA2147754 A CA 2147754A CA 2147754 A1 CA2147754 A1 CA 2147754A1
Authority
CA
Canada
Prior art keywords
endoglin
tgf
beta
polypeptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002147754A
Other languages
English (en)
Inventor
Michelle Letarte
Joan Massague
Carmelo Bernabeu
Sela Cheifetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Consejo Superior de Investigaciones Cientificas CSIC
Memorial Sloan Kettering Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/968,953 external-priority patent/US5830847A/en
Application filed by Individual filed Critical Individual
Publication of CA2147754A1 publication Critical patent/CA2147754A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002147754A 1992-10-30 1993-10-26 Compositions et methodes pour modifier l'activite de regulation de tgf- .beta. Abandoned CA2147754A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96895492A 1992-10-30 1992-10-30
US07/968,953 US5830847A (en) 1992-10-30 1992-10-30 Soluble TGF-β-binding endoglin polypeptides and homodimers
US07/968,954 1992-10-30
US07/968,953 1992-10-30

Publications (1)

Publication Number Publication Date
CA2147754A1 true CA2147754A1 (fr) 1994-05-11

Family

ID=27130519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002147754A Abandoned CA2147754A1 (fr) 1992-10-30 1993-10-26 Compositions et methodes pour modifier l'activite de regulation de tgf- .beta.

Country Status (5)

Country Link
EP (1) EP0667870A4 (fr)
JP (1) JPH08504577A (fr)
AU (1) AU5541094A (fr)
CA (1) CA2147754A1 (fr)
WO (1) WO1994010187A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688409B2 (en) * 1993-11-19 1998-03-12 University Of Sydney, The A method for preventing or controlling cataract
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
CA2156767A1 (fr) * 1994-08-25 1996-02-26 Kenichi Matsunaga Agent liant pour facteur de croissance
NZ528320A (en) * 2001-02-23 2005-07-29 Wyeth Corp Composition for inducing cartilaginous tissue formation and maintenance comprising a non-culture expanded CD105+ cells and a BMP
EP2862867A3 (fr) 2005-10-25 2015-08-05 The Johns Hopkins University Procédés et compositions pour le traitement du syndrome de Marfan et troubles associés
EP2230252A1 (fr) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation de la thromborésistance endothéliale
ES2538265T3 (es) 2006-10-03 2015-06-18 Genzyme Corporation Anticuerpos contra TGF-beta para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
EP3181580A1 (fr) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Antagonistes des récepteurs alk1 et ligands et leurs utilisations
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3398966A1 (fr) 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Procédés et compositions pour moduler l'angiogenèse et composition de péricytes
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
CN108341863A (zh) * 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
CA2853484C (fr) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine dans le traitement d'une maladie fibreuse
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
KR20220013459A (ko) 2013-10-25 2022-02-04 악셀레론 파마 인코포레이티드 섬유화 질환을 치료하기 위한 엔도글린 펩티드
EP3064222B1 (fr) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Médicament thérapeutique contenant un inhibiteur de tgf-beta signal pour des maladies associées à la mort cellulaire du réticulum endoplasmique dans l'endothélium de la cornée
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Also Published As

Publication number Publication date
JPH08504577A (ja) 1996-05-21
WO1994010187A1 (fr) 1994-05-11
EP0667870A1 (fr) 1995-08-23
AU5541094A (en) 1994-05-24
EP0667870A4 (fr) 1998-04-01

Similar Documents

Publication Publication Date Title
US5830847A (en) Soluble TGF-β-binding endoglin polypeptides and homodimers
CA2147754A1 (fr) Compositions et methodes pour modifier l'activite de regulation de tgf- .beta.
JP4124815B2 (ja) ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
Boulay et al. The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors
US6365712B1 (en) Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
US8012704B2 (en) Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
Nagel et al. Genomic organization, splice variants and expression of CGM1, a CD66‐related member of the carcinoembryonic antigen gene family
McCuaig et al. mmCGM1a: a mouse carcinoembryonic antigen gene family member, generated by alternative splicing, functions as an adhesion molecule
JP2013237670A (ja) 酸化ｌｄｌ受容体に対するヒトモノクローナル抗体及びその医薬用途
WO1998025946A1 (fr) Anticorps monoclonaux specifiques des cadherines de cellules endotheliales et leurs utilisations
US20020123617A1 (en) Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof
US7138243B2 (en) NTB-A, a surface molecule involved in natural killer cells activity
JPH1084976A (ja) 新規ヒトｇ−蛋白質結合レセプター
AU5670396A (en) Cd6 ligand
Budt et al. Secreted CEACAM1 splice variants in rat cell lines and in vivo in rat serum
EP2078752A2 (fr) Réactions de ALK-1 au TGF-beta et des signaux traversant SMAD-1 et SMAD-5
US6740735B1 (en) DNA encoding human apoB48R: a monocyte-macrophage apolipoprotein B48 receptor gene and protein
JP2001503248A (ja) 補体活性化を改変するための方法及び手段
WO2001023561A2 (fr) Nouveaux polynucleotides codant des proteines contenant des sequences repetees de thrombospondine type 1 (tsrx)
Sun et al. Expression of glycoprotein VI in vascular endothelial cells
Sassetti The CD34 family
WO1996040913A1 (fr) Gene codant un vecteur humain des folates reduits (rfc) et procedes de traitement de cellules cancereuses resistantes au methotrexate et a transport deficient

Legal Events

Date Code Title Description
FZDE Dead